BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Salgia R, Singal AG. Hepatocellular Carcinoma and Other Liver Lesions. Medical Clinics of North America 2014;98:103-18. [DOI: 10.1016/j.mcna.2013.09.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Skill NJ, Butler J, O’brien DC, Kays JK, Kubal CA, Liangpunsakul S, Ninad N, Maluccio MA. Financial Burden of Liver Transplant vs Resection for Hepatocellular Carcinoma. Transplantation Proceedings 2019;51:1907-12. [DOI: 10.1016/j.transproceed.2019.04.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Jinjuvadia R, Salami A, Lenhart A, Jinjuvadia K, Liangpunsakul S, Salgia R. Hepatocellular Carcinoma: A Decade of Hospitalizations and Financial Burden in the United States. Am J Med Sci 2017;354:362-9. [PMID: 29078840 DOI: 10.1016/j.amjms.2017.05.016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
3 Kilcup N, Tonkopi E, Abraham RJ, Boyd D, Kehoe S. Composition-property relationships for radiopaque composite materials: pre-loaded drug-eluting beads for transarterial chemoembolization. J Biomater Appl 2015;30:93-103. [PMID: 25690386 DOI: 10.1177/0885328215572196] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
4 El Mahdy HA, Abdelhamid IA, Amen AI, Abdelsameea E, Hassouna MM. MicroRNA-215 as a Diagnostic Marker in Egyptian Patients with Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2019;20:2723-31. [PMID: 31554369 DOI: 10.31557/APJCP.2019.20.9.2723] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
5 Martens MH, Lambregts DMJ, Kluza E, Beets-tan RGH. Tumor Response to Treatment: Prediction and Assessment. Curr Radiol Rep 2014;2. [DOI: 10.1007/s40134-014-0062-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
6 Liberati S, Morelli MB, Amantini C, Farfariello V, Santoni M, Conti A, Nabissi M, Cascinu S, Santoni G. Loss of TRPV2 Homeostatic Control of Cell Proliferation Drives Tumor Progression. Cells 2014;3:112-28. [PMID: 24709905 DOI: 10.3390/cells3010112] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
7 Taflin H, Hafström L, Holmberg E, Castedal M, Lindnér P. The impact of increased immigration to Sweden on the incidence and treatment of patients with HCC and underlying liver disease. Scandinavian Journal of Gastroenterology 2019;54:746-52. [DOI: 10.1080/00365521.2019.1627580] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Edenvik P, Davidsdottir L, Oksanen A, Isaksson B, Hultcrantz R, Stål P. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice? Liver Int 2015;35:1862-71. [PMID: 25524812 DOI: 10.1111/liv.12764] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
9 Wang P, Shen Y, Zhao L. Chitosan nanoparticles loaded with aspirin and 5-fluororacil enable synergistic antitumour activity through the modulation of NF-κB/COX-2 signalling pathway. IET Nanobiotechnol 2020;14:479-84. [PMID: 32755957 DOI: 10.1049/iet-nbt.2020.0002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Hochnadel I, Kossatz-Boehlert U, Jedicke N, Lenzen H, Manns MP, Yevsa T. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. Hum Vaccin Immunother. 2017;13:2931-2952. [PMID: 29112462 DOI: 10.1080/21645515.2017.1359362] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]